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Abstract:
As the catalyst for the rate-limiting reaction step of de novo DNA synthesis, the
enzyme ribonucleotide reductase (RNR) stands as an important biochemical hub within
the cell. During rapid cell growth and DNA damage, an increase in RNR activity is
observed that corresponds with the increased rate of DNA replication. Furthermore,
inhibition of RNR in cancerous cells has shown to slow tumor growth, indicating that the
enzyme is a legitimate target for anti-cancer therapy. While several drugs that function as
RNR inhibitors have proven effective against certain forms of cancer, chemotherapy that
targets RNR could always be improved in both efficacy and specificity (i.e. minimization
of side-effects). Thus, further knowledge related to more effective means for RNR
inhibition has direct clinical applications and is a topic of great research interest.
This proj ect ainls to develop and implement a fluorescence-based assay for the
determination of the dissociation constants-a measure of two molecules' affinity for one
another in solution-between different forms of RNR from the baker's yeast
Saccharomyces cerevisiae (wild-type and the E689A mutant) and its natural protein

inhibitor Smll. The exact structural details of how these two proteins interact-details
that could provide a valuable framework for the design of novel RNR drugs-are
currently unknown, although it has been confirmed that Smll binds the large subunit of
yeast RNR, known as Rnrl. Therefore, the assay will be designed to quantify Rnrl-Smll
interactions, which will be measured indirectly through changes in the fluorescence
anisotropy of Smll as the concentration of Rnr I is increased. By comparing the
differences in Smll 's binding affinity for wild-type Rnrl versus the E689A Rnrl mutant,
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it is hoped that valuable information will be obtained about which Rnr I residues interact
with Smll and are involved in its binding.

Background:
Ribonucleotide reductase (RNR) is an enzyme found in all organisms and is
responsible for catalyzing the conversion of ribonucleosides-UDP, CDP, GDP, and
ADP-to 2'-deoxyribonucleoside diphosphates I (2' -deoxy-TDP is synthesized by
thymidilate synthase2). As such, RNR is responsible for maintaining the proper balance
of cellular dNTP pools, which must be finely tuned to insure that DNA replication takes
place in a timely and accurate manner. If dNTP pools are too low, replication rates
decrease; if too high, mutation rates of vital genes increase. Either way, the ultimate
result is cell death. Thus, RNR is regulated extensively, both at the transcriptionae and
allosteric4 levels, as well as through subcellular localization in eukaryotes.
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Due to

human RNR's status as a target for effective anti-cancer treatment via drugs such as
hydroxyurea6,7 and Gemcitabine8 , which interfere with RNR activity, there has been
much interest in the molecular/structural basis of RNR catalysis and inhibition, as well as
in the structural details of RNR's interactions with these drugs. 9 More recently,
considerable research has been devoted to the development of peptidomimetic-based
RNR inhibitors (molecular mimics of short peptides) that bind the enzyme with high
specificity and affinity.lO,Il,12,13 Generally speaking, novel and increasingly effective
mechanisms for RNR inhibition are currently highly sought after due to the great
potential for clinical applications.
Mechanistically, RNR is unique among enzymes in its utilization of long-range,
radical-dependent electron transport for catalysis-in fact, it was the first protein radical
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discovered. I4 However, because the RNR reaction mechanism itself is so highly
conserved throughout the species, different types of RNR are distinguished on the basis
upon which they generate their free radical, and are divided accordingly into three main
classes: I, II, and III. Class I RNR-the type found in eukaryotes-utilizes a diiron
cofactor to produce a radical on one of the protein's tyrosine residues. I5 ,I6 The major
steps of the Class I reaction mechanism, as determined in Escherichia coli RNR, include:
(1) the generation of a tyrosyl radical (Y122) on the

p subunit Rnr2,

(2) the transport of

the electron from Rnr2 to the catalytic subunit Rnr1 via several amino acid intermediates,
(3) the formation of a catalytic thiyl radical (C439) on Rnr1, and (4) the reduction of the
nucleoside in the active site (involving the residues C439, C462, C225, and E441)
through a 3'-keto radical intermediate. I ?
While E. coli RNR has provided mechanistic insight that is extendable to the
human enzyme, it has also been shown that S. cerevisiae RNR is a good model for
obtaining relevant structural information due to its high sequence identity (66%) and
similarity (83%) with human RNR. The yeast enzyme complex exists as an

a2PW hetero

oligomer in solution, with both a-subunits catalytically active. The a-subunit, or large
subunit, Rnr1 (888 residues; 99.6 kDa) contains the catalytic site as well as the allosteric,
effector, and specificity sites essential for proper regulation of substrate specificity. The

~

subunit Rnr2 (399 residues; 46.1 kDa), as mentioned above, contains the diiron radical
essential for initiation of catalysis. Finally, the

Wsubunit Rnr4 (345 residues;

40.0 kD),

which is found in S. ceravisiae but not E. coli, is thought to either provide structural
support for the complex18,19 or assist in iron binding. 20 Recently, the three-dimensional x
ray crystal structures of S. cerevisiae Rnr 1 bound with various substrates and effectors
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were solved by Xu et al 2006. These structures, in addition to providing a completely
ordered picture of the catalytic site that was consistent with the previously proposed
catalytic nlechanism, also revealed another important region of the protein, Loop 2,
which, by undergoing conformational shifts in an effector-dependent manner, confers
RNR with the ability to preferentially bind and reduce one particular nucleoside over the
others. 21
The regulation of RNR in S. cerevisiae, in addition to the previously mentioned
mechanisms, also involves the inhibitory action of the 12 kD (104 residue) protein
Smll. 22 While its exact mechanism for RNR inhibition is currently unknown, Smll has

been shown to bind to the Rnrl subunit in a 1: 1 ratio with a dissociation constant of 0.4
uM. Also, the presence of Smll in a RNR solution does not affect the Rnr 1
dimer/monomer equilibrium or Rnr 1-Rnr2 association!dissociation equilibria, suggesting
the possibility that the Rnr 1 binding site for Smll is distinct from those for Rnr 1
(dimerization), Rnr2, and Rnr4. Interestingly, while there has not been an Smll gene
identified in mammals, yeast Smll nevertheless binds to and inhibits mouse Rnrl. 23 This
indicates that the structural details of RnrI-Snl11 interactions-details currently unknown
due to the lack of a crystal structure of the complex-may be relevant to the development
of novel human RNR inhibitors, thereby justifying investigation of the yeast Smll-Rnrl
binding mechanism on the basis of drug design.
Often, when the three-dimensional X-ray crystal structure of a protein complex is
lacking (such as is the case with the Smll-Rnrl pair), valuable structural information
about protein-protein binding can still be obtained via less direct means. One such
approach involves measuring and comparing the binding affinities, usually expressed as
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dissociation constants (KJ), of various mutant binding-pairs (in which one or more known
residues are altered in the protein about which structural data is desired) to the wild-type
pair. Relative changes in affmity indicate that the altered residue is somehow involved
directly or indirectly-in the binding of the other protein. Therefore, by analyzing many
different mutants, a picture can be built--one residue at a time--of the regions within the
protein likely involved in binding.
Here, the above approach was applied to the Smll-Rnr 1 binding pair through the
development and utilization of a fluorescence-based assay for the measurement of
dissociation constants between Snlll and two forms of Rnrl: wild-type (WT) and the
E689A mutant. By comparison of the KJ obtained for WT Rnrl and a previously
published value (15), an effective benchmark would be provided for the assay's accuracy
and precision. The E689 A Rnr 1 was selected for KJ measurement due to previous
biochemical data that showed that the IC so value (the concentration of Smll at which half
of the activity of Rnrl is lost) is lower in the mutant than in the wild-type. If this is the
case, and if Smll inhibition does in fact rely on direct Rnrl binding, then the E689A
Rnrl'SmllKJ should be lower than that of the WT (eg: it should bind more tightly to the
mutant than to the wild type protein).
The assay was designed to be capable of screening, over short periods of time,
many different Rnr 1 mutants for Smll affinity changes, and also to provide a measurable
signal that was highly specific to the actual binding event (Le.-a signal relatively
impervious to random molecular events). Essentially, the assay involved: (1) the labeling
of the C14S/S60C Smll double mutant with a small molecule fluorescent probe: thiol
reactive Alexa C5 Maleimide 350 dye 24, (2) the titration of the labeled Smll solution

7
with Rnr 1 (either wild-type or E689A mutant) with simultaneous measurement of
changes in fluorescence, and (3) the generation of an Smll-Rnr 1 binding curve from
which a dissociation constant could be extracted.
There are several practical reasons that Smll was chosen over Rnr 1 to serve as the
fluorescent protein. First, because this assay addresses the Smll binding site on Rnrl, not
vice-versa, the affinity of multiple Rnrl variants (here, Wt and the E689A mutant) for a
single Smll mutant (here, the C14S/S60C double-mutant) must be analyzed. If Smll is
labeled, then as long as the desired yield is obtained, only one reaction round is
necessary. Second, for this assay, a high signal to noise ratio depends on a large change
in the tumbling rate of the fluorescent protein (see next paragraph through p. 8). Because
changes in tumbling rate are proportional to changes in molecular mass (as affected by a
binding event), Smll was also selected as the fluorescent protein because its molecular
weight (12 kD) is much smaller than that of Rnrl (99.6 kD); upon binding, the effective
change in MW of the fluorescent protein is thus nearly 1000%. Lastly, the C14S/S60C
Smll mutant, because it contains a single cysteine residue, was chosen on the basis that
tagging it with the thiol-reactive Alexa Fluor tag would produce only one conjugation
state.
To address the issue of specificity, the measured quantity of the assay was not
merely scalar fluorescence intensity, but rather fluorescence anisotropy (r). A description
of the degree to which a solution of fluorescent molecules, upon excitation by plane
polarized light, fluoresces in a direction parallel to the excitation beam, anisotropy is by
definition a population event. 25 ,26 It hinges on the fact that the only fluorophores excited
by plane-polarized light in a solution are those whose dipole nloments-at the instant the
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beam passes through the solution-are aligned with the plane of the beam. Anisotropy is
best understood mathematically through the following equation, where it is defined in
terms of polarized emission intensity (I) that is either parallel (III) or perpendicular (lj..)
to the polarized excitation beam (17, 18):

(Eq. 1) r = (III 11)1(1 11+ 2 Ii)
If anisotropy, in the case of freely tumbling fluorophores in solution,

IS

conceptualized as the degree to which an excitation signal's direction vector is
"randomized" by the fluorophores' random (Brownian) tumbling, then it becomes
apparent why relative values of anisotropy for a given solution are proportional to
relative fluorophore tumbling rates. In fact, anisotropy is related to the tumbling rate
(specifically, the rotational correlation time, <1» and the lifetime of the fluorophore,

't,

through the Perrin equation, in which ro is the limiting (maximum theoretical) anisotropy
(18):

(Eq. 2) r

rol(1 + [TI (/>})

Because fluorescence lifetime is a kinetic parameter, its value can be assumed as
constant for a given fluorophore. Thus, a change in the fluorescence anisotropy of a given
solution will be directly proportional to the change in the fluorophore' s rotational
correlation time, which can also be expessed as a function of solution viscosity (1]),
temperature (T), and fluorophore volume (V) (R equals the ideal gas constant) (18):

(Eq. 3) (/>

=

1] VIRT

For a protein, volume is proportional to the molecular nlass; therefore, changes in
protein mass-inherent in any protein-protein binding event-correlate directly to
changes in that protein's fluorescence anisotropy according to equations 2 and 3. Here,
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the measurement of changes in a fluorescence-labeled Smll solution's anisotropy upon
incremental addition (titration) of Rnrl provides binding data in the form of percent
saturation (% bound or % unbound). This is represented by the following equation, in
which r is the measured anisotropy at a given titrant (Rnr I) concentration, rF is the
anisotropy of the solution when it is completely in the unbound state (as is assumed to be
the case when no Rnrl is present), and

rB

is the anisotropy of the solution when it is

completely in the bound state (assumed to be equal to the maximum r observed during an
Smll/Rnrl titration) (18):

(Eq. 4) % Bound = (r

rF)/(rB

rF)

Of course, if the quantum yield (Q) of the fluorescent probe changes as Smll
transitions from bound to unbound states, then the measured anisotropy values will be
weighted in favor of the state with the higher Q (i.e. the higher fluorescence emission
intensity) and will not serve as an accurate representation of percent saturation. In this
case, a correction factor must be applied to equation (above) to produce equation (below),
in which (QslQP) is the ratio of the fluorophore's quantum yields in the bound and
unbound states. Here, QF is assumed to be equal to the fluorescence emission intensity of
the Smll solution in the absence of Rnr1, and QB is assumed to be equal to that when the
maximum amount ofyRnrI has been added (18):

(Eq. 5) % Bound

(r - r.tJ/[(rB - r)(QB/QF) + (r - rF)}
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Materials and Methods:
Expression and Purification of S. cerevisiae Smll S60C Mutant:

BL21 (DE3) pLysS Escherichia coli cells transfonned with the S60C/C14S Smll
expression plasmid were cultured overnight at 37 deg. C in 50 mL of Luria Broth in the
presence of 34 mg/L of Chloramphenicol and 100 nlg/L of Ampicillin. Ten milliliters of
this culture were then added to each of four 2 L flasks containing 500 mL of Terrific
Broth (TB) with 34 mg/L Chloramphenicol and 100 mg/L Ampicillin. The cells were
grown at 37 deg. C to an optical density (OD) of 0.6 AU measured at a wavelength of
600 nm, induced to express S60C/C14S Smll with the addition of isopropyl-B-D
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM, and incubated at 37
deg. C for 3 hours. They were then harvested by centrifugation at 5,000 x g (all
centrifugation was perfonned at 4 deg. C.), resuspended in Smll buffer (50mM Tris pH
7.4, 10% Glycerol, ImM EDTA, ImM PMSF, 5mM DTT, Ix Complete protease
inhibitor), flash-frozen in liquid nitrogen, and stored at -80 deg. C.
At each stage of the purification process, the presence of S60C/C 14S Smll was
confinned by SDS-PAGE (Fig. 1). An Amersham G-75 gel filtration column was
equilibrated with 150 mL of the following buffer: 50mM Tris pH 7.4, 100 mM KC1, 10%
Glycerol, ImM EDTA, 5mM DTT. The resuspended Smll cells were lysed by thawing at
4 deg C, and benzonase (1-3 microliters per sample) was added to degrade cellular DNA.
Upon loss of viscosity, the lysate was centrifuged at 150,000 x g for 1 hour. The
supernatant was collected and a 25% w/v ammonium sulfate cut was perfonned at 4 deg.
C for 1 hour, followed by centrifugation at 12,000 x g for 30 minutes. The resulting
ammonium sulfate pellet was resuspended in 2.5ml of Smll buffer and spun at top speed
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in a Fisher Accuspin Micro tabletop centrifuge to precipitate excess ammonium sulfate.
The supernatant was collected and immediately injected into the equilibrated G-75
column. S60C/C14S Smll was purified via size exclusion chromatography (Fig. 3). The
presence of S60C/C 14S Sml1 was verified by SDS-PAGE (Fig. 1), and the concentration
was determined by a Bradford protein assay. DTT and excess salt were removed from the
purified S60C/C 14S Smll sample via a GE-Amersham PD-10 Desalting Column, and a
Millipore Centriplus YM -10 centrifuge filter was employed to adjust the S60C Sml1
concentration to 100 J.tM (1.2 mg/mL).
Reaction ofS60C Smll with Alexa Fluor C5 Maleimide Fluorophore:

Immediately following purification and concentration, the C 14S/S60C Sml1
protein sample was conjugated with Invitrogen Alexa 350 Maleimide dye, according to
the proprietary protocol27 at roonl temperature (see "Appendix: Alexa Fluor 350
Maleimide Step-by-Step Conjugation Protocol"). In parallel, a separate control solution
was prepared composed of buffer plus the same concentration of free Alexa fluor dye.
These reactions were terminated after 2 hours by the addition of excess glutathione (,..., 5
mg glutathione per 1 mg Alexa dye), and the C 14S/S60C Sml1 containing sample was
repurified via size exclusion chromatography as before (Fig. 4). This sample's buffer was
then exchanged by ultrafiltration, and the presence of the Alexa fluorlS60C Smll
conjugate (Alexa-Smll) was verified by SDS-PAGE (Fig. 2) and a fluorescence emission
scan (Fig. 4). The conjugate was then appropriately aliquoted, flash-frozen in liquid
nitrogen, and stored at -80 deg. C.
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Expression/Purification of Wi/d- Type and E 689A S. cerevisiae Rnr1:

Both wild-type yeast Rnr1, which was provided by Sanath Wijerathna, as well as
the E689A mutant were expressed and purified in the same manner. BL21 (DE3) pLysS
cells transformed with the respective yeast Rnr 1 expression plasmids were cultured
overnight at 37 deg. C in 10 mL of TB containing 100 mglL Ampicillin and 34 mglL
Chloramphenicol. The cells were then grown at 37 deg. C in (4) 2 L flasks, each
containing 500 mL of the same media. When the OD at 600 nm reached 0.6 AU, the cells
were chilled for 15 minutes at 4 deg. C, induced with 0.5 mM IPTG, and allowed to
express yRnr 1 overnight at 15 deg. C. Afterwards, the cells were harvested by
centrifugation at 5000 x g for 30 min. at 4 deg. C and stored at -80 deg. C.
The cells were thawed on ice and resuspended in a lysis buffer consisting of 100
mM KCI, 50 mM HEPES-KCI pH 7.0, 5 mM MgCh, 5% (v/v) glycerol, 5 mM DTT, Ix

Complete protease inhibitor, and 1 mM PMSF. Following multiple passages through
French pressure at 12,000 psi, the lysate was centrifuged at 12,000 x g for 30 nlin. A
1.5% weight/volume streptomycin sulfate cut was then performed at 4 deg. C for 30 min.,
followed by 30 nlin. of centrifugation at 15000 x g. A 29% m/v ammonium sulfate cut
was carried out on the collected supernatant, followed by centrifugation at 15,000 x g for
30 min. The supernatant was discarded and the ammonium sulfate pellet was stored at
-80 deg. C.
All Rnr I purification steps were performed at 4 deg. C. First, the ammonium
sulfate pellet was thawed on ice, resuspended in buffer (50 mM HEPES-KCI pH

7.0, 5

mM DTT, 5 mM MgCI2, 5% (v/v) glycerol, 1 mM PMSF, 1 x Complete protease

inhibitor tablet), and passed through a GE-Amersham PD-IO desalting column.
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Additional protease inhibitor was added and the mixture was incubated with Rnr2/Rnr4
peptide affinity resin for 1 hour. The column was washed, first with 20 mL of buffer, then
with 30 mL buffer + 0.2 M KCl. Rnr 1 was eluted with 10 mL of Rnr 1 buffer + 1 M KCI,
concentrated via ultrafiltration, frozen in liquid nitrogen, and stored at -80 deg. C.

Fluorescence Intensity and Anisotropy Measurements:
All fluorescence measurements were performed at 25 deg. C on a Perkin Elmer
LS 55 Fluorescence Spectrometer coupled with Perkin Elmer FL Winlab software
(Version 4.00.03). First, the Alexa-Smll and Rnr1 samples were thawed on ice and their
concentrations were verified to 10% precision with a three-point-triplicate Bradford
protein assay. The concentration of Rnr1 was then adjusted so that the desired titration
increment (Wt

60 nM; E689A

43.7 nM) had a volume of 1 flL. Next, Alexa-Smll

was mixed in an omnidirectional quartz fluorescence cuvette with "Rnr1 buffer"
(mentioned earlier:

to a final concentration of 0.50 flM. A fluorescence emission

intensity scan was performed on the Alexa-Sm11 solution, using the following parameters
in the 'Scan' program (single-scan mode) of Winlab: Excitation (lambda)
Emission range = 400-595 nm; Em.lExc. slit width

346 nm;

3 nm; (lambda)/min. = 300. This

was followed by a time-based intensity emission scan with the following parameters:
Excitation (lambda) = 346 nm; Emission (lambda) = 440 nm; Em.lExc. slit width

3 nm;

time = 60 sec. (the fluorescence buffer emission profile was subtracted as background in
both cases).
After completion of the emission scan, the "Reads" program was opened in
Winlab and "Anisotropy" mode was selected. Following the calculation of G-factors, the
Alexa-Smll solution was titrated with Rnr1 (Wt or E689A) and its fluorescence

14

anisotropy measured in a stepwise fashion with the following parameters: Excitation
(lambda): 346 nnl; emission wavelength: 440 nm; slit-widths: 3 nm; Integration Time: 30
sec. When the anisotropy appeared to have leveled off near its nlaximum value, one final
"saturating" titration increment (containing lOx Rnr 1 relative to the previous titration
increments) was added and the resulting anisotropy nleasured. Finally, a time based
intensity emission scan was performed on the saturated Alexa-SmlllRnrl solution (same
parameters as mentioned earlier for the "Smll- only" solution). This entire titration was
triplicated for both Wt and E689A yRnrl. Control titrations also followed this protocol,
and were performed once for both Wt and E689A Rnrl by replacing Alexa-Smll with an
equimolar amount of Alexa-glutathione (Alexa-GSH) conjugate.
Data Analysis:

All fluorescence data (Figs. 5-9) were exported directly from FL Winlab to
Microsoft Excel. Fluorescence intensity emission scan data were used to not only
establish the presence of fluorescent Alexa-Smll (Fig. 5), but also to establish the
quantum yield ratio for Alexa-Smll in its bound and unbound states, QB/QF (Figs. 6-7).
The Alexa-glutathione "control titration" anisotropy data were treated as background
noise and were subtracted from the corresponding WT RnrllAlexa-Smll and E689A
Rnr 11Alexa-Smll measured anisotropy values. The resultant standardized values (Fig. 8)
were then combined with the respective quantum yield ratios in Equation 5 (see p. 9) to
obtain values for the "fraction of Smll bound by Rnr 1" and generate binding curves for
Alexa-Smll-WtRnrl and Alexa-Smll-E689A-RnrI (Fig. 9). Finally, these binding
values were exported from Excel to the Graphpad Prism data analysis suite in order to
extract the respective dissociation constants. This was accomplished in "XY Graphs,"
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utilizing the "One-site Binding (Hyperbola)" equation with an initial value for K<i of OA
~lM

and a constraint on maximum binding of less than 1.00. The resulting regressions

(Fig. 10) and their corresponding statistical data (Table 1) were exported to and formatted
in Excel.

ResultslDiscussion:
Initial fluorescence emission intensity scans confirmed both the presence and
viability of Alexa-Smll (for the control runs, Alexa-GSH) as a fluorophore. The emission
intensity for 0.5 JlM Alexa-Smll at 440 nm (2.1 x104 AU) provided a relative quantum
yield value for Alexa-Smll in the unbound state (Qf). As increasing amounts of yRnrI
were added to the Alexa-Smll solution, a maximum fluorescence anisotropy value was
approached, indicating that the Alexa-Sml1 was near saturation (% Bound", 100). The
emission intensity values at 440 nm for 0.5 JlM Alexa-Smll in the presence of 2.34 JlM
WT Rnr1 and 1.32 JlM E689A yRnrI provided relative quantum yield values for Alexa
Smll in the bound state (QB): 2.9 x 104 RU and 2.3 x 104 RU, respectively. These values
combined with QF to calculate quantum yield ratios (QB/QF) for wild-type and E689A
yRnrl of 1.4 and 1.1, respectively. The fluorescence anisotropy curves (Fig. 8) provide
clear qualitative indication that the E689A mutant binds C14S/S60C Smll more tightly
than WT Rnr 1.
The dissociation constant data calculated in GraphPad Prism for each titration are
summarized in Table 1. For the WT RnrIlCI4S-S60C Smll pair, the average measured

K<i equals 0.3 j.tM,

0.09 JlM, a value that falls within the error range of the previously

published value ofOA j.tM, +1- 0.1 j.tM (15), as well as has a degree of precision similar to
previously published fluorescence anisotropy data. 28 ,29,30 This result provides strong
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indication that the assay described here is indeed a legitimate method for quantification
ofRnrllSmll binding. For the E689A RnrllC14S-S60C Smll pair, the average measured

KJ of 0.1 J..lM, +/- 0.04 J..lM, provides evidence that Smll binds this mutant more tightly
than wild-type, an observation that is in agreement with previous biochemical data of
heightened E689A inhibition by Smll. For both Rnr1 variants, the statistical range of the
individual KJ values was less than 25% of the average value. R2 values ranged from 0.83
to 0.85 for WT Rnrl/C14S-S60C Smll and from 0.85 to 0.87 for E689A RnrllC14S
S60C Sml1.
When considering the application of this fluorescence assay, as described, to other
Rnr1 mutants for further characterization of the SmlllRnrl binding mechanism, it
becomes clear that there is room for optimization. As reflected in the standard error for
the .Ki values obtained, there were factors that significantly limited the assay's precision.
Most prominently, the Bradford protein assay, which was used to determine the initial
concentrations of Smll and Rnr1, is only capable of 90% accuracy; the use of a more
precise method for concentration measurenlent would likely decrease the standard error
significantly. Other sources of error include: precision limitations of volume
measurements (pipet calibration, etc.), calibration of the data acquisition setup
(spectrometer optics, etc.), and the inclusion of a limited number of data points in each
binding curve (an increase in the number of titration increments from a few dozen to a
few hundred would provide further refinement). In the future, minimization of these
variables in this assay-perhaps through the incorporation of automated, high-throughput
methods--could allow for the measurement of dissociation constant values to two
significant figures. This would provide the precision necessary for detection of the small
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changes in affinity from Rnr 1 mutant to mutant that could be crucial to a true
understanding of what is taking place structurally.
In conclusion, this fluorescence-based method provides a viable template for
characterization of the Smll/Rnr1 binding mechanism through the relative binding
affinities of Rnr 1 mutants. Sm11' s heightened binding of the E689 A Rnr 1 mutant is one
piece of the "mechanistic puzzle", but many other Rnr1 residues need to be addressed
before a picture of how these two proteins interact structurally can begin to emerge.

Figures/Da ta:
Figure 1: 15% SDS-PAGE Gel ofC14S/S60C Smll Purification. Lanes, from left to right: (1) Bio-Rad Low
Range SDS-PAGE Molecular Markers, (2) Smll eel/lysate, (3) Smll post-ammonium sulfate cut, (3) Smll
supernatant post-tabletop centrifugation, (5) Smll after G75 size-exclusion purification (before
conjugation with Alexa Fluor 350 C5 Maleimide). Disregard lane 4.
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Figure 2: 15% SDS-PAGE Gel ofAlexa-tagged C14S/S60C Smll and Wt yRnr1.
Lanes, from left to right: (1) Bio-Rad Low Range SDS-PAGE Molecular Markers, (2,3) disregard, (4)
C14S/S60C Smll after conjugation with Alexa Fluor 350 C5 Maleimide and second size-exclusion
purification, (5) Wt yRnr1 after P7-peptide affinity chromatography and concentration.

Figure 3: Size-exclusion chromatogram ofSmll (third peak to the right) after G75 size-exclusion
purification (before conjugation with Alexa Fluor 350 C5 Maleimide).
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Figure 4: Size exclusion chromatogram ofC14S/S60C Smll after conjugation with Alexa Fluor 350 C5
Maleimide and second size-exclusion purification.
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Figure 6
TIme-Based Fluorescence Intensity Scan: Alexa-Sml1lWt yRnr1
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Figure 7

Time Based Fluorescence Intensity Scan: Alexa-SmI1/E689AyRnr1
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Figure 8

sta ndardized FL Anisotropy: Wt yRnrl/Alexa-Smll and E689A yRnrl/Alexa
Smll
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Bin ding Data: Wt yRnrl/C14S- S60C Smll and E689A yRnrl/C14S-S60C Smll
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Figure 10

Regression Data for yRnrl/Smll Binding
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TABLE 1: Regression Statistical Data
C14S-560C Sml1fIM yRnr1 Regression Analysis
Run 1
Run 2
Run 3
Equation: One site binding (hyperbola)
Best-fit values
BMAX

KD
Std. Error
BMAX
KD
95%Confidence Intervals
BMAX
KD
Goodness of Fit
Degrees of Freedom

R2
Absolute Sum of Squares
Sy.x
Constraints
BMAX

KD
Data
Number of Xvalues
Number of Yreplicates
Total number of values
Number of missing values

Average

Kd Range/Avg. Kd C14S-S60C Sml1/E689A yRnr1 Regression Analysis
Run 1
Run 2
Run 3

1
0.2476

1
0.33

1
0.3107

1
0.2961

0.06783
0.0708

0.08469
0.1012

0.08636
0.1003

0.07962667
0.09076667

0.8613 to 1.000
0.1028 to 0.3923

0.8268 to 1.000 0.8234 to 1.000
0.1229 to 0.5370 0.1055 to 0.5159

29
0.8492
0.4441
0.1 237
BMAX< 1.000
KD> 0.0

29
0.8433
0.4806
0.1287
BMAX <1.000
KD > 0.0

31
1
31
0

29
0.8307
0.5416
0.1367

1
0.1134

1
0.1287

1
1
0.1411 0.12773333

0.07368
0.03771

0.07278
0.03951

0.08877
0.07841
0.05033 0.04251667

29
0.84106667
0.48876667
0.1297

20
0.8577
0.2992
0.1223
BMAX < 1.000
KD> 0.0

31
1
31
0

Kd Range/Avg. Kd

0.8463 to 1.000
0.8482 to 1.000
0.8148 to 1.000
0.03475 to 0.1921 0.04630 to 0.2111 0.03616 to 0.2461

BMAX < 1.000
KD > 0.0
31
1
31
0

0.278284363

Average

31
1
31
0

20
0.8744
0.2534
0.1126
BMAX < 1.000
KD > 0.0

22
1
22
0

20
20
0.8469 0.85966667
0.3383 0.29696667
0.1301 0.12166667
BMAX < 1.000
KD> 0.0

22
22

22
1
22

0

0

1

22
1
22
0

0.216858038
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Appendix: Alexa Fluor Maleimide Step-by-Step Conjugation Protocol
Note: Care must be taken to protect Alexa jluorophore from light as much as possible

before and during conjugation.

1. Immediately prior to use, prepare 1-10 mM stock solution of Alexa Fluor
Maleimide by dissolving in appopriate volume ofDMSO.
2. Adjust protein (Smll) concentration to 50-100 JlM in suitable buffer (50mM Tris
pH 7.4,100 mM KCl, 10% Glycerol, 1mM EDT~ without DTT) at room
temperature.
3. Place the Smll solution in a Falcon tube and stir. Add Alexa Fluor
Maleimide/DMSO solution (10 moles Alexa fluor per mole Sml1) dropwise. Cap
the Falcon tube and allow the reaction to proceed while stirring for 2 hours.
4. After 2 hours, terminate the reaction by adding an excess amount of glutathione.
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